Share this video  

GU Cancers 2023 | The clinical impact of TRITON3 on the potential role of rucaparib in the future treatment of mCRPC

Alan Haruo Bryce, MD, Mayo Clinic, Rochester, MN, discusses the possible clinical impact of the Phase III TRITON3 (NCT02975934) trial assessing rucaparib versus physician’s choice in patients with chemotherapy-naïve metastatic castration resistant prostate cancer (mCRPC) with BRCA1/2 (BRCA) or ATM alterations. OS maturity was 54% in the BRCA subgroup and 59% in the ITT population. Although the results are showing a trend towards the superiority of rucaparib versus physician’s choice, OS has not yet reached maturity and so the impact on survival outcomes has yet to be established. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.